Human papillomavirus vaccine initiation among 9–13-year-olds in the United States  by Donahue, Kelly L. et al.
Preventive Medicine Reports 2 (2015) 892–898
Contents lists available at ScienceDirect
Preventive Medicine Reports
j ourna l homepage: ht tp : / /ees .e lsev ie r .com/pmedrHuman papillomavirus vaccine initiation among 9–13-year-olds in the United States
Kelly L. Donahue ⁎, Kristin S. Hendrix, Lynne A. Sturm, Gregory D. Zimet
Indiana University School of Medicine, Dept. of Pediatrics, 410 West 10th Street, Suite 1001, Indianapolis, IN 46202, USAAbbreviations: ACIP, Advisory Committee on Immuniz
⁎ Corresponding author.
E-mail address: kldonahu@iu.edu (K.L. Donahue).
http://dx.doi.org/10.1016/j.pmedr.2015.10.003
2211-3355/© 2015 The Authors. Published by Elsevier Inca b s t r a c ta r t i c l e i n f oAvailable online 21 October 2015Keywords:
Early adolescence
Healthcare providers
ImmunizationThe quadrivalent and 9-valent human papillomavirus (HPV) vaccines are licensed for administration among
9–26-year-old males and females, with routine vaccination recommended for 11–12-year-olds. Despite the
availability of the vaccine at younger ages, few studies have explored vaccine uptake prior to age 13, and national
HPV vaccination surveillance data is limited to 13–17-year-olds. Our objective was to examine rates and
predictors of HPV vaccine initiation among 9–13-year-olds in the United States. A national sample of mothers
of 9–13-year-olds in the United States (N = 2446) completed a 2014 Web-based survey assessing
socio-demographic characteristics, child's HPV vaccination history, provider communication regarding the
vaccine, and other attitudes and behaviors pertaining to vaccination and healthcare utilization. The main
outcome measure was child's initiation of the HPV vaccine (i.e., receipt of one or more doses). Approximately
35% of the full sample and 27.5% of the 9–10-year-olds had initiated HPV vaccination. Females were more likely
thanmales to have initiatedHPVvaccination by the age of 13 but not by younger ages. Strength of health provider
recommendation regarding HPV vaccination was a particularly salient predictor of vaccine initiation.
Approximately a third of children may be initiating the HPV vaccine series before or during the targeted age
range for routine administration of the vaccine. Because coverage remains below national targets, further
research aimed at increasing vaccination during early adolescence is needed. Improving providers' communication
with parents about the HPV vaccine may be one potential mechanism for increasing vaccine coverage.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Introduction
Human papillomavirus (HPV) is a highly prevalent sexually
transmitted infection affecting both males and females (Hariri
et al., 2011; Forhan et al., 2009; Giuliano et al., 2008). HPV is the
primary cause of cervical cancer and leading cause of other anogenital
and oropharyngeal cancers, in addition to causing genital warts
(Schiffman et al., 2007; Munoz et al., 2004; Watson et al., 2008;
Jayaprakash et al., 2011). Vaccination provides effective protection
against HPV and its associated adverse health outcomes (Baandrup
et al., 2013; Giuliano et al., 2011; Hariri et al., 2013; Markowitz et al.,
2013). The three available HPV vaccines each protect against two
“high-risk” HPV types (HPV16 and 18) associated with the majority of
HPV-related cancers. The quadrivalent and 9-valent vaccines also
protect against two “low-risk” types (HPV6 and 11) associated with
90% of genital warts. The 9-valent vaccine protects against ﬁve
additional “high-risk” types (HPV31, 33, 45, 52, and 58) responsible
for 10% of HPV-related cancers (Petrosky et al., 2015). While the
three-dose vaccine series may be initiated as early as age nine
(Centers for Disease Control and Prevention, 2010), the Advisoryation Practices.
. This is an open access article underCommittee on Immunization Practices (ACIP) has recommended
that the vaccine be routinely administered to 11–12-year-old
females and males (quadrivalent and 9-valent only) since 2006 and
2011, respectively. However, only 60% of female and 41.7% of male
13–17-year-olds have received at least one dose of the vaccine as of
2014 (Reagan-Steiner et al., 2015). Limited research exists regarding
rates of vaccine uptake at ages 9–12.
In addition to socioeconomic status, race/ethnicity, and general and
vaccine-speciﬁc healthcare utilization behaviors (Centers for Disease
Control and Prevention, 2013; Kessels et al., 2012; Reiter et al., 2013),
healthcare provider recommendation appears to be a key factor in
parents' decision to vaccinate their children against HPV (Dorell et al.,
2013; Holman et al., 2013; Stokley et al., 2014; Donahue et al., 2014).
However, most studies of predictors of vaccine uptake have focused
on adolescents ages 13 and older. Greater understanding of factors
inﬂuencing initiation prior to and during the recommended age
range for routine HPV vaccination may identify potential targets for
intervention to increase vaccination coverage.
Our objectivewas to explore rates and predictors of HPV vaccine ini-
tiation among 9–13-year-old males and females in the United States.
Because limited data are available regarding HPV vaccine initiation
prior to age 13, one aim of the study was to estimate the vaccine
initiation rate among 9–12-year-olds. We were also able to compare
our observed rate of initiation by age 13 to that of previously publishedthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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additional aim of the study was to examine characteristics of “early”
initiators (i.e., individuals receiving at least one dose of the HPV vaccine
by ages 9–10, prior to the targeted age for routine recommendation) as
well as predictors of initiation among childrenwhohad already reached
the targeted age range for routine administration (i.e., ages 11 and up).
Methods
Sample
Data were collected in August 2014 as part of a larger Web-based
survey assessing attitudes and behaviors related to HPV and inﬂuenza
vaccination in a national sample of mothers of 9–13-year-olds in the
United States. The study was approved by the IRB at Indiana University.
Data collection was facilitated by Survey Sampling International (SSI),
a survey research company that maintains national panels of adults in
37 countries. Each panel member may participate in up to four surveys
annually, and participants are entered into a lottery to win a monetary
prize through SSI. E-mail invitations were sent at random to members
of SSI's U.S. panel meeting the study's target demographic. Initially,
3208 panelists responded to a generic e-mail invitation to participate
in a survey, with 2860 women (89%) agreeing to complete the survey
after being presented with a brief description of the study. Of those
agreeing to participate, 2446 (86%) met the eligibility criteria for partic-
ipation (i.e., theywere 18 years of age or older and themother or female
legal guardian of at least one 9–13-year-old child who lived in their
household). Participants with more than one 9–13-year-old child
were prompted to answer questions about their youngest child in this
age range. Although the participants were recruited nationally, the
sample does not constitute a nationally representative sample.
Measures
We assessed HPV vaccination history using mother report of the
number of doses of the HPV vaccine received by the child. Children
who had received at least 1 dose of the vaccine were categorized as
HPV vaccine initiators.
Additional items related to HPV vaccination included mother report
of whether the child's healthcare provider had discussed with her that
her child could receive the HPV vaccine, and, if so, the strength of
recommendation (i.e., “In your opinion, how strongly did your child's
healthcare provider recommend that that your child receive the
HPV vaccine?”), which was reported on a 5-point scale ranging
from strongly discouraged to strongly recommended. These two items
were combined and collapsed into four categories: “did not discuss,”
“no recommendation” (combining responses of “neither recommended
nor discouraged,” “discouraged,” or “strongly discouraged” due to low
frequency of individual categories), “recommended,” and “strongly
recommended.” Mothers also reported whether the target child had
any older siblings and whether any of these siblings had received the
HPV vaccine.
Mothers responded to ﬁve items pertaining to general beliefs about
the beneﬁts of immunization (e.g., “It is important that people get
vaccinated so that they can protect their health”) using a 5-point
response scale (Rickert et al., 2014) (Chronbach's alpha = .78), with a
higher score on each item reﬂecting stronger beliefs about the beneﬁts
of vaccination. The scale reﬂects the perceived beneﬁts construct of
the Health Beliefs Model (Skinner et al., 2015), with items chosen
based on previous reports assessing factors inﬂuencing parents' immu-
nization of early adolescents (Rickert et al., 2014). "Perceived beneﬁts
of vaccination" was included as a continuous variable in our analyses,
calculated using the mean of the ﬁve items.
Mothers reported on multiple healthcare-utilization behaviors
such as whether or not the child had visited a doctor, nurse, or other
healthcare provider in the past year; whether the child has a regularhealthcare provider (deﬁned as a healthcare provider who knows
the child and his/her health history), the type of location where the
child typically visits a healthcare provider; and whether the child
received the inﬂuenza vaccine during the most recent inﬂuenza season
(approximately September 2013 to March 2014).
Sociodemographic characteristics included child's age, gender,
race/ethnicity, geographic region, and health insurance type, as
these variables have previously been associated with disparities in
adolescent HPV vaccination.
Statistical analyses
Children whose mothers reported uncertainty regarding the
number of doses received or for whom vaccination history was
missing (n = 261) were excluded from analyses predicting vaccine
HPV initiation, resulting in a total sample size of 2185, or 89.3% of
eligible participants. HPV vaccination data were more likely to be
missing among target children (n = 261) who were male, belonged
to racial/ethnic minorities, and did not have private insurance, and
also more likely to be missing among 9-year-olds and less likely
among 13-year-olds. No differences were found with regard to
geographic region.
First, we compared HPV vaccine initiators to non-initiators with
regard to categorical variables using chi-square tests of independence.
We conducted a t-test of independent samples to assess whether
there were differences between initiators and non-initiators with
regard to mothers' perceived vaccine beneﬁts. All variables found to
have signiﬁcant bivariate associations with initiation were then includ-
ed in a multivariate logistic regression model comparing initiators to
non-initiators. Lastly, we used chi-square tests of independence to
examine differences between initiators and non-initiators separately
among two age groups: 9–10-year-olds (those younger than the age
range targeted for routine recommendation) and 11–13-year-olds.
Results
Descriptive statistics for all variables are presented in Table 1.
Frequencies and means correspond to the sample of 2185 participants
providing initiation data. Of these participants, 34.9% had initiated the
vaccine series (i.e., one or more doses had been received).
Comparing HPV vaccine initiators and non-initiators
Table 1 presents the results of chi-square tests of independence
comparing HPV vaccine initiators and non-initiators with α = .05.
A signiﬁcantly higher percentage of initiators were age 12 or 13,
whereas a signiﬁcantly higher percentage of non-initiators were
age 9, 10, or 11. A signiﬁcantly higher percentage of initiators were
female, belonged to a racial/ethnic minority, had public health insur-
ance or were uninsured, had an older sibling who received the HPV
vaccine, received the ﬂu vaccine during the most recent ﬂu season,
had visited a healthcare provider in the past year, and typically re-
ceived healthcare services in a location other than a private ofﬁce.
Mothers of initiators reported signiﬁcantly greater perceived general
beneﬁts of vaccination. A signiﬁcantly higher percentage of initiators
had mothers who reported that their child's healthcare provider had
recommended or strongly recommended HPV vaccination, while a
signiﬁcantly higher percentage of non-initiators had mothers who
reported that their child's healthcare provider had not discussed
the possibility of vaccinating their child against HPV.
All variables found to have signiﬁcant bivariate associations
with initiation were then included in a logistic regression model
predicting vaccine initiation. Table 2 presents odds ratios representing
the effect of each measure in univariate models (Table 2, Model
1) followed by a multivariate model (Table 2, Model 2). In the
multivariate model, relative to mothers who reported that a healthcare
Table 1
Sample characteristics of 9–13-year-olds in the U.S. who have and have not initiated HPV
vaccination.
Full sample Initiateda Not initiated
Measure (n= 2185) (n= 763) (n= 1422) p value
Age, n (%)
9 635 (29.1) 163 (21.4)f 472 (33.2)f b .001
10 454 (20.8) 136 (17.8)f 318 (22.4)f
11 398 (18.2) 121 (15.9)f 277 (19.5)f
12 389 (17.8) 194 (25.4)f 195 (13.7)f
13 307 (14.1) 149 (19.5)f 158 (11.1)f
Gender, n (%)
Female 1257 (57.5) 464 (60.8) 793 (55.8) .02
Male 928 (42.5) 299 (39.2) 629 (44.2)
Race/ethnicity, n (%)b
Minority or multiracial/ethnic 720 (33.8) 303 (40.7) 417 (30.0) b .001
White 1413 (66.2) 441 (59.3) 972 (70.0)
Geographic region, n (%)c
Northeast 391 (18.3) 141 (18.9) 250 (17.9) .35
Midwest 500 (23.4) 176 (23.6) 324 (23.3)
South 814 (38.1) 265 (35.5) 549 (39.4)
West 433 (20.2) 164 (22.0) 269 (19.3)
Puerto Rico 1 (.0) 0 (.0) 1 (.1)
Health insurance type, n (%)
Private 1298 (59.4) 426 (55.8) 872 (61.3) .01
Public/self-pay 887 (40.6) 337 (44.2) 550 (38.7)
Provider communication about
HPV vaccine, n (%)
Did not discuss 989 (46.7) 69 (9.0)f 929 (69.5)f b .001
No recommendationd 185 (8.7) 65 (8.5) 120 (8.4)
Recommended 504 (23.8) 302 (39.6)f 202 (14.2)f
Strongly recommended 438 (20.7) 327 (42.9)f 111 (7.8)f
Sibling HPV vaccination status,
n (%)
Received 627 (29.2) 356 (47.5) 271 (19.4) b .001
Did not receive/no older
sibling
1519 (70.8) 393 (52.5) 1125 (80.6)
Flu vaccine in most recent ﬂu
season, n (%)
Received 1284 (59.1) 573 (75.4) 711 (50.4) b .001
Not received 887 (40.9) 187 (24.6) 700 (49.6)
Perceived beneﬁts of
vaccination, mean (SD)
3.54 (.79) 3.61 (.74) 3.50 (.81) .002
Doctor, nurse, or other
healthcare provider visit
in past year, n (%)
Yes 2042 (93.6) 731 (96.1) 1311 (92.3) .001
No 139 (6.4) 30 (3.9) 109 (7.7)
Regular healthcare provider,
n (%)
Yes 2087 (95.8) 737 (96.7) 1350 (95.3) .11
No 92 (4.2) 25 (3.3) 67 (4.7)
Service location, n (%)
Private ofﬁce 1744 (79.8) 540 (70.8) 1204 (84.7) b .001
Other locatione 441 (20.2) 223 (29.2) 218 (15.3)
Note: Data were collected via a Web-based survey in 2014.
a Among vaccine initiators, dose completion reported as follows: 1 dose, n = 283;
2 doses, n = 212; 3 doses, n = 268.
b Child race/ethnicitywas self-designated by participants as follows: African American/Black,
14.3%; American Indian, 2.3%; Asian, 4.7%; Hispanic or Latino, 13.0%; White, 75.2%;
Native Hawaiian or other Paciﬁc Islander, .9%; Other, 1.8%; No response, .3%. Mothers
were asked to select multiple race/ethnicities when applicable. Participants were
categorized as belonging to a racial/ethnic nonminority (i.e., White) or minority,
(including 21.0% of participants who reported a single minority race/ethnicity and
12.8% who indicated multiple race/ethnicities).
c Geographic locationwasdetermined frommother's reported zip code and categorized
based on the U.S. census region.
d Category includesmothers reporting that the vaccinewas “neither recommended nor
discouraged,” n= 174, “discouraged,” n= 9; or “strongly discouraged,” n= 2.
e Includes community health clinic, university-based health clinic, emergency room or
urgent care clinic, or other
f For variables consisting ofmore than 2 categories, denotes signiﬁcant group differences
for that category at p b .05.
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more likely to report initiation if they reported that their child's
healthcare provider (a) discussed but did not speciﬁcally recommendvaccination, OR = 8.97 (5.74–14.00), (b) recommended vaccination,
OR = 21.88 (15.38–31.12), or (c) strongly recommended vaccination,
OR = 38.60 (26.61–56.00). Increased odds of initiation were also
found with every one-year increase in age, OR = 1.23 (95% CI
1.13–1.35); having an older sibling who received the HPV vaccine,
OR = 2.52 (1.94–3.27); and having received the ﬂu vaccine last ﬂu
season, OR = 2.51 (1.91–3.31). However, decreased odds of initiation
were found when receiving services in a private ofﬁce, OR = .39
(.28–.54) for those with private insurance, OR = .72 (.55–.94), and for
females, OR = .76 (.59–.98). Minority status, perceived beneﬁts of vac-
cination, and past-year healthcare provider visit were not signiﬁcant
predictors of initiation in the multivariate model.
Because observed data suggest a substantial gender difference in
vaccination, with females more likely to initiate vaccination than
males, we conducted additional exploratory analyses to clarify the neg-
ative effect of female gender in our multivariate logistic regression
model. We found that this effect was likely due to the association
between gender and provider communication—when included in the
multivariate logistic regression model, a gender × communication
interaction termwas statistically signiﬁcant. To illustrate the interaction
between child gender and healthcare provider communication (Fig. 1),
we estimated the predicted probability of HPV vaccine initiation as a
function of gender at each level of provider communication using esti-
mates obtained frommultivariate logit regressionmodels and including
all remaining variables from the multivariate model in Table 2 (Long
and Freese, 2005). The pattern observed in Fig. 1 suggests that as the
strength of provider recommendation increased, the predicted proba-
bility of initiation also increased. Provider discussionof HPV vaccination,
regardless of recommendation, appeared to have a stronger effect on
initiation among males than among females. The predicted probability
of initiation without discussion for females (.05) was signiﬁcantly
lower than for males (.07, 95% CI for difference: .001, .030.) The
predicted probability of initiation was signiﬁcantly higher for males
than for females following discussion without recommendation
(.39 vs. .33, 95% CI for difference: .003, .122), recommendation (.61 vs.
.54, 95% CI for difference: .005, .129), and strong recommendation
(.73 vs. .68, 95% CI for difference: .004, .109).
Chi-square tests of independence also suggested signiﬁcant differ-
ences in healthcare provider communication by gender (χ2 = 40.13,
df = 3, p b .001). Among mothers of daughters, 41.2% (n = 503)
reported that no discussion about HPV vaccination occurred; 8.6%
(n = 105) reported that the HPV vaccine was discussed but either
discouraged or not recommended; and 26.3% (n = 321) and 23.9%
(n=291) reported that their child's healthcare provider recommended
or strongly recommended HPV vaccination, respectively. Among
mothers of sons, 54.2% (n = 485) reported that no discussion
about HPV vaccination occurred; 8.9% (n = 80) reported that the
HPV vaccine was discussed but either discouraged or not recom-
mended; and 20.4% (n = 183) and 16.4% (n = 147) reported
that their child's healthcare provider recommended or strongly
recommended HPV vaccination, respectively.
Comparing HPV vaccine initiators and non-initiators by age group
Initiation was reported by 27.5% of 9–10-year-olds and 42.4% of
11–13-year-olds. We examined factors associated with HPV vaccine
initiation vs. non-initiation by ages 9–10 as well as initiation vs. non-
initiation by ages 11–13 (Table 3) using chi-square tests of
independence, α= .05. A gender difference was found in initiation
by ages 11–13 but not by ages 9–10. Because existing research
shows that there are signiﬁcant gender differences in HPV vaccination
amongolder adolescents,we conducted additional chi-square tests to ex-
plore whether the rate of initiation differed by gender at each age within
the target age range. No signiﬁcant differenceswere foundwith regard to
the rates of initiation between females and males by age 9 (25.4% vs.
26.0%, respectively, p = .88), age 10 (32.7% vs. 26.4%, p = .15), age 11
Table 2
Odds ratios (OR) from univariate (Model 1) and multivariate (Model 2) logistic regression models predicting HPV vaccine initiation among 9–13-year-olds.
Model 1 Model 2
Variable OR 95% CI p value OR 95% CI p value
Age 1.33 (1.25–1.40) b .001 1.23 (1.13–1.35) b .001
Gender
Male (ref. category) 1.00 1.00
Female 1.23 (1.03–1.47) .02 .76 (.59–.98) .04
Race/ethnicity
Minority or multiracial/ethnic (ref. category) 1.00 1.00
White .62 (.52–.75) b .001 .84 (.65–1.09) .19
Health insurance type
Public/self-pay (ref. category) 1.00 1.00
Private health insurance .80 (.67–.95) .01 .72 (.55–.94) .01
Provider communication regarding HPV vaccine
Did not discuss (ref. category) 1.00 1.00
No recommendation given 8.39 (5.63–12.50) b .001 8.97 (5.74–14.00) b .001
Recommendation given 23.15 (16.88–31.75) b .001 21.88 (15.38–31.12) b .001
Strong recommendation given 45.61 (32.52–63.98) b .001 38.60 (26.61–56.00) b .001
Sibling HPV vaccination status
Did not receive/no older sibling (ref. category) 1.00 1.00
Older sibling received HPV vaccine 3.76 (3.09–4.56) b .001 2.52 (1.94–3.27) b .001
Flu vaccine in most recent ﬂu season
Did not receive (ref. category) 1.00 1.00
Received 3.02 (2.48–3.67) b .001 2.51 (1.91–3.31) b .001
Perceived beneﬁts of vaccination 1.19 (1.07–1.34) .002 1.04 (.88–1.23) .64
Doctor, nurse, or other healthcare provider visit in past year
No (ref. category) 1.00 1.00
Yes 2.03 (1.34–3.07) .001 .86 (.47–1.56) .61
Location where typically receives services
Other location (ref. category) 1.00 1.00
Private clinic .44 (.35–.54) b .001 .39 (.28–.54) b .001
Note: Data were collected via a Web-based survey in 2014.
895K.L. Donahue et al. / Preventive Medicine Reports 2 (2015) 892–898(29.8% vs. 31.4%, p= .74), or age 12 (54.1% vs. 44.4%, p= .06). By age 13,
a signiﬁcantly higher proportion of females had initiated vaccination
(53.8%, versus 40.7% of males, p= .02).
Chi-square tests of independence also indicated differences in
health insurance type by initiation status among 9–10-year-olds,
but not among 11–13-year-olds, with a signiﬁcantly greater percent-
age of those who had initiated the vaccine by ages 9–10 either re-
ceiving publicly funded health insurance or being uninsuredFig. 1. Predicted probability of HPV vaccine initiation by child gender and healthcare provider co
multivariate logit models including variables shown in Table 2. Estimated values of all remain
predicted probability. Data were collected via a Web-based survey in 2014.(45.8%) compared to non-initiated 9–10-year-olds (39.8%). A signif-
icantly higher percentage of those initiated by ages 11–13 had visit-
ed a healthcare provider in the past year (96.5%) compared to those
not initiated by ages 11–13 (91.4%), while this difference was not ob-
served among 9–10-year-olds. Those initiating by ages 11–13 also
had mothers who reported signiﬁcantly higher perceived beneﬁts
of vaccination than those not initiating by ages 11–13, M(SD) 3.68
(.75) vs. 3.45 (.81).mmunication regarding HPV vaccination. Predicted probabilities were estimated based on
ing variables held at their means. Error bars represent the 95% conﬁdence interval of the
Table 3
Comparison of HPV vaccine initiation status by ages 9–10 and 11–13.
Vaccination status by ages 9–10 Vaccination status by ages 11–13
Initiated Not Initiated Initiated Not Initiated
Measure (n= 299) (n= 790) p value (n= 464) (n= 630) p value
Gender, n (%)
Female 173 (57.9) 434 (54.9) .39 291 (62.7) 358 (56.8) .05
Male 126 (42.1) 356 (45.1) 173 (37.3) 272 (43.2)
Race/Ethnicity, n (%)
Minority or multiracial/ethnic 121 (41.4) 230 (29.9) b .001 182 (40.3) 186 (30.1) .001
White 171 (58.6) 540 (70.1) 270 (59.7) 431 (69.9)
Geographic region, n (%)
Northeast 52 (17.8) 136 (17.6) .23 89 (19.6) 114 (18.4) .90
Midwest 70 (20.4) 170 (22.0) 106 (23.3) 154 (24.9)
South 103 (35.3) 325 (42.0) 162 (35.7) 224 (36.2)
West 67 (22.9) 141 (18.2) 97 (21.4) 126 (20.4)
Puerto Rico 0 (.0) 1 (.1) 0 (.0) 0 (.0)
Health insurance type, n (%)
Private 162 (54.2) 483 (61.1) .04 264 (56.9) 388 (61.6) .12
Public/self-pay 137 (45.8) 307 (38.9) 200 (43.1) 242 (38.4)
Provider communication about HPV vaccine, n (%)
Did not discuss 32 (11.0)a 589 (76.8)a b .001 28 (6.1)a 339 (57.2)a b .001
Discouraged/No recommendation 18 (6.2) 43 (5.6) 47 (10.2) 77 (13.0)
Recommended 113 (38.7)a 80 (10.4)a 189 (40.9)a 122 (20.6)a
Strongly recommended 129 (44.2)a 55 (7.2)a 198 (42.9)a 55 (9.3)a
Sibling HPV vaccination status, n (%)
Received 144 (49.3) 142 (18.3) b .001 212 (46.3) 128 (20.6) b .001
Did not receive/no older sibling 148 (50.7) 632 (81.7) 246 (53.7) 492 (79.4)
Flu vaccine in most recent ﬂu season, n (%)
Received 234 (78.5) 435 (55.5) b .001 339 (73.4) 276 (44.2) b .001
Not received 64 (21.5) 349 (44.5) 123 (26.6) 349 (55.8)
Perceived beneﬁts of vaccination, mean (SD) 3.50 (.71) 3.54 (.81) .41 3.68 (.75) 3.45 (.81) b .001
Doctor, nurse, or other healthcare provider visit in past year, n (%)
Yes 284 (95.3) 735 (93.0) .17 447 (96.5) 574 (91.4) .001
No 14 (4.7) 55 (7.0) 16 (3.5) 54 (8.6)
Regular healthcare provider, n (%)
Yes 293 (98.0) 757 (96.1) .12 444 (95.9) 591 (94.3) .14
No 6 (2.0) 31 (3.9) 19 (4.1) 36 (5.7)
Service location, n (%)
Private ofﬁce 205 (68.6) 673 (85.2) b .001 335 (72.2) 530 (84.1) b .001
Other location 94 (31.4) 117 (14.8) 129 (27.8) 100 (15.9)
p value is for two-sided test, α b .05. Chi-square and t-tests were used to compare vaccine initiators and non-initiators with regard to categorical and continuous variables, respectively.
Note: Data were collected via a Web-based survey in 2014.
a For variables with more than two categories, this denotes signiﬁcant group differences for speciﬁc category at p b .05.
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We explored HPV vaccine initiation among 9–13-year-olds in the
United States. To our knowledge, this is one of the ﬁrst studies subse-
quent to the ACIP recommendation for routine immunization in early
adolescence that assesses rates of HPV vaccine initiation among both
males and females in this age range. This study adds to literature sug-
gesting that provider communication and/or recommendation regard-
ing HPV vaccination is a key factor in parents' vaccination decisions,
suggesting that this may also be a key factor at earlier ages. We were
also able to explore potential differences between children who
initiated vaccination prior to and during the targeted ages for routine
recommendation.
Ourmultivariate analyses indicated that child age, provider commu-
nication regardingHPV vaccination,ﬂu vaccine history, sibling receipt of
the HPV vaccine, health insurance type, and typical location of provider
visits were signiﬁcant predictors of initiation among 9–13-year-olds.
Older age was associated with increased likelihood of having initiated
the vaccine series, which is in keepingwith previous estimates of cover-
age across later adolescence (Stokley et al., 2014; Dempsey et al., 2010;
National Center for Health Statistics and National Health Interview
Survey, 2010). The results of our study suggest that this effect is also
present in the early adolescent period. Higher initiation rates across ad-
olescence occur in conjunction with an increase in healthcare provider
recommendation of vaccination across the age range (Vadaparampil
et al., 2011; Roland et al., 2014; Weiss et al., 2010; Malo et al., 2014).Our results suggest that encouraging provider recommendation of
vaccination at earlier ages could result in increased initiation rates at
earlier ages, as discussed below. Additionally, parents who opt to
vaccinate their children against the seasonal ﬂumay be more accepting
of other non-mandated immunizations such as the HPV vaccine, and
those who have older vaccinated children may also be more accepting
of the HPV vaccine for their younger children. High acceptance of HPV
vaccination may be more common among parents of children receiving
care outside of private clinics and/or who lack private health insurance
beneﬁts (Zimet et al., 2005). Again, our ﬁndings extend previous
research among older adolescents into the younger end of the vaccine-
eligible range. Interestingly, mothers' perceived beneﬁts of vaccination,
while associated with likelihood of initiation in bivariate analyses,
were no longer a signiﬁcant predictor of initiation in the multivariate
analysis, suggesting that other factors may ultimately be more salient
to parents' decisions regarding immunization.
Healthcare provider communication regarding HPV vaccination was
a particularly strong predictor of initiation across our sample. This
ﬁnding regarding younger children is consistent with previous research
among parents of older adolescents indicating the signiﬁcant impact of
provider recommendation on parents' decision making surrounding
HPV vaccination (Dorell et al., 2013; Holman et al., 2013; Stokley et al.,
2014; Donahue et al., 2014; Alexander et al., 2014).. Unfortunately,
almost half of mothers in our sample reported that their child's
healthcare provider did not discuss HPV vaccination. When discussion
did occur, however, it most commonly involved a recommendation or
897K.L. Donahue et al. / Preventive Medicine Reports 2 (2015) 892–898strong recommendation; Fig. 1 suggests that the majority of mothers
would elect to vaccinate their son or daughter if it was recommended.
Provider recommendation may increase parent perception of the
vaccine as safe and effective, leading to increased rates of initiation
(Staras et al., 2014).
Our ﬁnding that initiation among males may be more strongly
affected by healthcare provider recommendation could reﬂect the rela-
tive recency of the ACIP's routine recommendation for males compared
to females and the associated barriers to vaccination, such as less
awareness of the importance of male vaccination among providers as
well as among parents of sons. Such barriers are commonly reported
by parents of sons, who may be willing to vaccinate once such barriers
are addressed (Donahue et al., 2014).
Interestingly, the gender gap in initiation did not begin to emerge in
our sample until around ages 12 to 13. Similarities in initiation rates
among males and females at younger ages may reﬂect a trend toward
increased availability and equality of administration of the vaccine for
males, as licensure and routine recommendation of the vaccine for
males (2009 and 2011, respectively) occurred more recently than for
females (2006 and 2007, respectively).
Although the rates were similar among both genders at ages 11–12,
coverage remains discouragingly low given that this is the age range in
which the vaccine should be routinely administered. Missed opportuni-
ties for vaccination are frequent—the Centers for Disease Control and
Prevention estimates that 91.3% of females born in 2000 would have
received at least one dose of the HPV vaccine by age 13 if it had been
administered during healthcare visits when they received another
immunization (Stokley et al., 2014). In our own sample, 92.3% of
9–13-year-olds who had not yet initiated the HPV vaccine had seen a
healthcare provider within the past year, highlighting the importance
of healthcare provider communication regarding vaccination whenever
such an opportunity arises. In conjunction with previous research, our
ﬁndings suggest that provider-focused interventions aimed at promot-
ing communication about the HPV vaccine may reduce such missed
opportunities and increase HPV vaccination coverage among youth
(Perkins et al., 2015). Improving provider communication about the
HPV vaccine during the early adolescent age range may be particularly
beneﬁcial, as older adolescents tend to seek preventive care services
less frequently (Rand et al., 2007) and are also at greater risk for
experiencing HPV exposure prior to vaccination.
The study has several limitations. First, data were not collected from
a nationally representative sample. However, the demographics of our
sample are comparable to the most recent available U.S. census
estimates pertaining to the distribution of individuals across geographic
regions (U.S. Census Bureau) as well as the distribution of racial groups
among 9–13-year-olds (U.S. Census Bureau, 2015a,b). Second, parental
recall of vaccination history rather than immunization recordsmay pro-
duce accurate estimates of overall coverage but less accurate estimates
among racial minorities or individuals of lower socioeconomic status
(U.S. Census Bureau, 2015a,b). However, mother-reported vaccination
status may be more accurate than reports from other caregivers (Ojha
et al., 2013; Attanasio and McAlpine, 2014). Of note, the initiation rate
among 13-year-olds in our 2014 sample (females, 53.8%; males,
40.7%) is similar to coverage estimates for 13-year-olds in the 2014
NIS-Teen sample (females, 51.1%± 4.1; males, 38.9%± 4.2), conﬁrmed
via vaccination records (Reagan-Steiner et al., 2015). Third, it is possible
that parents who initiated vaccination and/or have more favorable
attitudes toward vaccination may be more likely to recall having
received positive provider communication about the vaccine. Similarly,
healthcare providers familiar with a family's vaccination attitudes and
history may be more likely to recommend the vaccine to vaccine-
friendly parents, and parents may seek out providers with whom they
share opinions about the importance of immunization practices. Fourth,
we did not assess age at initiation, meaning that some individuals
categorized as having initiated the vaccine by ages 11–13 may have in
fact initiated by ages 9–10, which would result in an underestimationof individuals as early initiators. Finally, datawere unavailable regarding
panel members who viewed the initial e-mail invitation for participa-
tion and opted not to participate, which prevented us from identifying
possible patterns of characteristics among nonresponders.
Conclusions
In one of the ﬁrst studies to assess rates of HPV vaccine initiation
among 9–13-year-olds following the ACIP recommendation for
routine immunization in early adolescence, we found that one quarter
of 9–10-year-olds had initiated the vaccine series, with coverage
increasing across the age range, and no gender differences in initiation
at younger ages. Strength of health provider recommendation to
parents about HPV vaccination emerged as a key factor in parents'
decision to vaccinate their children. Given the ubiquity of HPV and the
vaccine's effectiveness against adverse health consequence, the frequency
of initiation occurring prior to the targeted age for routine administration
holds promise; however, vaccination coverage among early adolescents
remains well below national health goals. Improvements in provider
communication with patients and their parents could substantially
contribute to HPV vaccination during early adolescence becoming
truly routine.
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